{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:14:12Z","timestamp":1790021652971,"version":"4.0.1"},"reference-count":107,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["L40TW012438"],"award-info":[{"award-number":["L40TW012438"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["5K12HD028827\u201033"],"award-info":[{"award-number":["5K12HD028827\u201033"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Sickle cell disease (SCD) is a major individual and public health challenge in sub\u2010Saharan Africa, where over 5 million affected individuals live and where access to disease\u2010modifying treatment is limited. Despite established safety and efficacy of hydroxyurea, its use is limited across the region due to inconsistent healthcare infrastructure, high medication and laboratory costs, inadequate clinician training, and persistent disease stigma. Practical hydroxyurea dosing strategies, integration into national health plans, and a stronger supply chain are necessary to improve access to this life\u2010saving medication. Newly approved medications, such as L\u2010glutamine and crizanlizumab, may provide additional benefits to select patients, but are expensive and unavailable. The increased mortality observed in people on voxelotor in Africa highlights the need to ensure the safety of any new medication in varied settings through high\u2010quality research conducted on the continent. Overall, holistic strategies are needed to improve SCD care in Africa, such as universal screening with connection to comprehensive care that includes disease\u2010modifying treatment, community and healthcare worker education, centers of excellence, and capacity building. SCD management in Africa can be transformed by addressing systemic barriers and leveraging collaborative partnerships, leading to reduced mortality and alleviation of the individual and economic burdens of the disease. It is a moral and economic imperative to prioritize access to SCD treatment in Africa, the region with the greatest disease burden globally.<\/jats:p>","DOI":"10.1002\/ajh.70226","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T10:46:21Z","timestamp":1773485181000},"page":"33-46","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advancing Sickle Cell Disease Treatment in Sub\u2010Saharan Africa: Challenges and Opportunities for Disease Modifying Therapies"],"prefix":"10.1002","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2017-2569","authenticated-orcid":false,"given":"Yvonne","family":"Dei\u2010Adomakoh","sequence":"first","affiliation":[{"name":"Department of Haematology University of Ghana Medical School\/Korle Bu Teaching Hospital  Accra Ghana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-6448","authenticated-orcid":false,"given":"Emmanuela E.","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Child Health Bugando Medical Centre  Mwanza Tanzania"},{"name":"Department of Paediatrics and Child Health Catholic University of Health and Allied Sciences  Mwanza Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5823-0218","authenticated-orcid":false,"given":"Alexandra","family":"Power\u2010Hays","sequence":"additional","affiliation":[{"name":"Division of Hematology Cincinnati Children\u2019s Hospital Medical Center  Cincinnati Ohio USA"},{"name":"Department of Pediatrics University of Cincinnati  Cincinnati Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(23)00118\u20107"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddab004"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201009\u2010702324.There"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/00034983.1979.11687243"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28620"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(17)30193\u20109"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201005\u2010783233"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/ASHEDUCATION\u20102014.1.418"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17658"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/09727531221108871"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.08.021103"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(12)61689\u20104"},{"key":"e_1_2_14_14_1","article-title":"Assessing the Burden of Sickle Cell Disease in Sub\u2010Saharan Africa A Cost\u2010Of\u2010Illness Study","volume":"2016","author":"Ngolet L. O.","year":"2020","journal-title":"Anemia"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916\u2010020\u201001557\u20102"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272491"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(23)00096\u20100"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2046535"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000582"},{"key":"e_1_2_14_20_1","unstructured":"K. A.Al\u2010busaidi \u201cSickle Cell Disease: A Strategy for the WHO African Region \u201dWorld Health Organization 2010 Provisiona 1\u201340 https:\/\/www.nber.org\/papers\/w15827.pdf."},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001143"},{"key":"e_1_2_14_22_1","first-page":"93","volume-title":"Transfusion Support for Patients With Sickle Cell Disease","author":"Power\u2010Hays A.","year":"2022"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/ASHEDUCATION\u20102013.1.439"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/AJH.27244"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010211666"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(19)30200\u20105"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(21)00209\u2010X"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.14383"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.4103\/ajts.AJTS_36_18"},{"key":"e_1_2_14_30_1","unstructured":"World Health Organization \u201cGlobal Status Report on Blood Safety and Availability 2021 \u201d2022 https:\/\/www.who.int\/publications\/i\/item\/9789240051683."},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.3324\/HAEMATOL.2020.270546"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537\u20102995.2009.02435.x"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.15585\/MMWR.MM6750A4"},{"key":"e_1_2_14_34_1","unstructured":"World Health Organization \u201cGlobal Status Report on Blood Safety and Availability \u201d2017 http:\/\/apps.who.int\/bookorders."},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16256"},{"key":"e_1_2_14_36_1","volume-title":"Global Consultation on Haemovigilance","author":"World Health Organization","year":"2012"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913\u2010021\u201007235\u20100"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2021.01.005"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13071"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1088827"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct0708272"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505183322001"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(11)60355\u20103"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214\u2010109X(14)70371\u20107"},{"key":"e_1_2_14_45_1","unstructured":"WHO Expert Committee \u201cThe Selection and Use of Essential Medicines: Report of the WHO Expert Committee \u201d2011 https:\/\/list.essentialmeds.org\/files\/trs\/uM2drf3qopwZIceChtyH0tqRGk7c86aLZRZYZimX.pdf."},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD\u20102017\u201006\u2010788935"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1813598"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(24)00078\u20104"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010210347"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017051"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25900"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(22)00405\u20107"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2000146"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(21)00368\u20109"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016620"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70071"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010163202"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400402"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273\u2010023\u201001294\u20103"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10112223"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.111300.1"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.770640"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.5334\/aogh.4132"},{"key":"e_1_2_14_64_1","unstructured":"Durgesh Nandan Jha \u201cDesi Sickle Cell Anaemia Drug to Cost Less Than 1% of International Versions \u201dTimes of India. March 18 2024 https:\/\/timesofindia.indiatimes.com\/city\/delhi\/desi\u2010sickle\u2010cell\u2010anemia\u2010drug\u2010hydroxyurea\u2010at\u20101\u2010cost\u2010of\u2010intl\u2010versions\/articleshow\/108570254.cms."},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26007"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25616"},{"key":"e_1_2_14_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24770"},{"key":"e_1_2_14_68_1","doi-asserted-by":"publisher","DOI":"10.4314\/ahs.v21i2.36"},{"key":"e_1_2_14_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28969"},{"issue":"2","key":"e_1_2_14_70_1","first-page":"61","article-title":"Treatment of Sickle Cell Disease\u2014Options and Perspective","volume":"13","author":"Abdel\u2010Hadi L.","year":"2023","journal-title":"American Journal of Blood Research"},{"key":"e_1_2_14_71_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24920"},{"key":"e_1_2_14_72_1","unstructured":"P.Bradt E.Spackman P.Synnot et\u00a0al. \u201cCrizanlizumab Voxelotor and L\u2010Glutamine for Sickle Cell Disease: Effectiveness and Value Evidence Report \u201d2020 https:\/\/icer\u2010review.org\/programs\/new\u2010england\u2010cepac\/."},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715971"},{"key":"e_1_2_14_74_1","unstructured":"E. L.Sciences \u201cEmmaus Life Sciences Provides Operational Updates \u201d2020 https:\/\/www.emmausmedical.com\/content\/news\/press\u2010releases\/emmaus\u2010life\u2010sciences\u2010provides\u2010operational\u2010updates\u2010213."},{"key":"e_1_2_14_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611770"},{"key":"e_1_2_14_76_1","unstructured":"Thalassaemia International Federation \u201cFDA Approves Oxbryta (Voxelotor) the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease \u201d2020 https:\/\/thalassaemia.org.cy\/news\/fda\u2010approves\u2010oxbryta\u2010voxelotor\u2010the\u2010first\u2010medicine\u2010specifically\u2010targeting\u2010the\u2010root\u2010cause\u2010of\u2010sickle\u2010cell\u2010disease\/."},{"key":"e_1_2_14_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(24)00384\u20103"},{"key":"e_1_2_14_78_1","unstructured":"European Medicines Agency \u201cAdakve\u2014referral \u201dMay 26 2023 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/adakveo#:~:text=On%2026%20May%202023%2C%20EMA's%20human%20medicines years%20and%20older%20with%20sickle%20cell%20disease.&text=The%20CHMP%20therefore%20concluded%20that%20its%20benefits%20do%20not%20outweigh%20the%20risks."},{"key":"e_1_2_14_79_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211001136"},{"key":"e_1_2_14_80_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1903212"},{"key":"e_1_2_14_81_1","article-title":"SCDAA Medical and Research Advisory Committee (MARAC) Statement: Pfizer's Voxelotor (Oxbryta) Withdrawal","volume":"27","author":"Day E.","year":"2024","journal-title":"MARAC Alert"},{"key":"e_1_2_14_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31475"},{"key":"e_1_2_14_83_1","volume-title":"Thrown Into Disarray","author":"Schneider M. E.","year":"2025"},{"key":"e_1_2_14_84_1","unstructured":"M. A.Pfizer Europe \u201cNotification to the CHMP\/EMA Secretariat of a Referral Under Article 20 of Regulation (EC) 726\/2004. July 30 \u201d2024 https:\/\/www.ema.europa.eu\/en\/documents\/referral\/oxbryta\u2010article\u201020\u2010procedure\u2010notification_en.pdf."},{"key":"e_1_2_14_85_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.1737"},{"key":"e_1_2_14_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24486"},{"key":"e_1_2_14_87_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmp2022125"},{"key":"e_1_2_14_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2024.102717"},{"key":"e_1_2_14_89_1","unstructured":"Thalassaemia International Federation \u201cFDA APPROVES AQVESME (mitapivat) | First Oral Therapy for Anaemia Across All Forms of Thalassaemia \u201d2025 https:\/\/thalassaemia.org.cy\/news\/fda\u2010approves\u2010aqvesme\u2010mitapivat\u2010first\u2010oral\u2010therapy\u2010for\u2010anaemia\u2010across\u2010all\u2010forms\u2010of\u2010thalassaemia\/#:~:text=According%20to%20recent%20market%20reporting %2C%20Medicare%2C%20private%20insurers."},{"key":"e_1_2_14_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(24)00319\u20103"},{"key":"e_1_2_14_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010204962"},{"key":"e_1_2_14_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u20102976"},{"key":"e_1_2_14_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27525"},{"key":"e_1_2_14_94_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2023.09.001"},{"key":"e_1_2_14_95_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002120"},{"key":"e_1_2_14_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2011.09.013"},{"key":"e_1_2_14_97_1","unstructured":"\u201cNovartis Announces Partnership with the American Society of Hematology to Fight Sickle Cell Disease in Sub\u2010Saharan Africa \u201dNovartis Press Release 2022 https:\/\/www.novartis.com\/news\/media\u2010releases\/novartis\u2010announces\u2010partnership\u2010american\u2010society\u2010hematology\u2010fight\u2010sickle\u2010cell\u2010disease\u2010sub\u2010saharan\u2010africa."},{"key":"e_1_2_14_98_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001484"},{"key":"e_1_2_14_99_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900105"},{"key":"e_1_2_14_100_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900100"},{"key":"e_1_2_14_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17429"},{"key":"e_1_2_14_102_1","doi-asserted-by":"publisher","DOI":"10.1080\/13557858.2010.541903"},{"key":"e_1_2_14_103_1","doi-asserted-by":"publisher","DOI":"10.2147\/ahmt.s223956"},{"key":"e_1_2_14_104_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc"},{"issue":"1","key":"e_1_2_14_105_1","first-page":"16","article-title":"Understanding the Impact of Stigma on People With Mental Illness","volume":"1","author":"Corrigan P. W.","year":"2002","journal-title":"World Psychiatry"},{"key":"e_1_2_14_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103018(19)30343\u20101"},{"key":"e_1_2_14_107_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14594.Sickle"},{"key":"e_1_2_14_108_1","unstructured":"A.Novartis \u201cGovernment of Ghana Makes Hydroxyurea Available to People With Sickle Cell \u201dCorporate Social Responsibility Newswire 2019 https:\/\/www.csrwire.com\/press_releases\/43038\u2010Government\u2010of\u2010Ghana\u2010Makes\u2010Hydroxyurea\u2010Available\u2010to\u2010People\u2010With\u2010Sickle\u2010Cell\u2010Disease\u2010Through\u2010First\u2010of\u2010Its\u2010Kind\u2010Public\u2010private\u2010Partnership\u2010With\u2010Global\u2010Medicines\u2010Company\u2010Novartis#."}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70226","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70226","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T10:46:57Z","timestamp":1773485217000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":107,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/ajh.70226"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70226","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"2025-06-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}